Survival in multiple myeloma stage III light chain varies from patient to patient, with a median survival of only about 6 months without treatment in patients with progressive disease.
One of the most distinctive features of multiple myeloma is the presence of malignant plasma cells that can be cloned indefinitely in the bone marrow of the patient. After their rapid multiplication, monoclonal immunoglobulins or light chains are present in the patient’s blood and urine, and the patient will develop osteoporosis or osteolytic lesions within a short period of time.
Multiple myeloma ISS staging divides patients into stages I, II, and III. Staging results show that the higher the grade, the worse the efficacy and the lower the survival rate. The light chain type is often combined with renal impairment, and the stage III light chain type generally has a poorer prognosis.
The median survival of patients in the progressive stage without treatment is only 6 months, and even with conventional chemotherapy, the median survival is no more than 3 years. A better chance of survival can be achieved with the promise of transplantation.
Specific survival is related to individual differences, severity of symptoms and treatment modalities. Patients are advised to seek prompt medical attention to prolong survival.